Innate Pharma S.A.

At this time, I would like to welcome everyone to the innate. At this time, I would like to welcome everyone to the innate pharma full year 2023 financial results and business update call. Today's conference is being recorded and all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press the star key followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one a second time. Thank you. And I will now turn the conference over to Henry Wheeler, Vice President of Investor Relations. Mr. Wheeler, you may begin.

Thank you. Good morning. Good afternoon and welcome, everyone. This morning, Innate issued a press release for our full year 2023 financial results and business updates. We look forward to highlighting the progress made during the year to date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IIS section of our website. On slide two, before we start, I'd like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risk and uncertainties that may cause actual results to differ from those forecasted. On slide three, on today's call, We will be joined by Herve Braille, our Interim Chief Executive Officer. Then we will hand over to Sonia Quarantino, our Chief Medical Officer, who will cover updates on the Kutumab and IPH65. We will then hand to Yanis Morel, Chief Operating Officer, who will then discuss ANCET and ABC platform updates. Frederic Lombard, our CFO, will cover the financials. And we're very pleased to welcome Arvind Sood, EVP US Operations, who will wrap up and close. Herve, I now hand the call to you.

Thanks, Henry. Good morning and good afternoon, everyone. I would just like first to recall that innate trauma is a very important play on the field of NK cell pharmacology and innate immunity manipulation. We address that through different mechanisms of actions where we have corresponding products. It's first about engaging NK cells as cytotoxic effectors to tumor cells, and that's the approach that the we implement with the Enquete platform, but also with the essential toxic antibody, Lapetamab. We've also been pioneering the field of checkpoint inhibitors of NK cells with Monalizumab, which is a checkpoint which is shared, which is targeting a checkpoint which is shared by different classes of effector cells, both NK and T cells. and eventually through addressing suppression of the toxic immune response through IPH 62 and 63, which addresses the adenosine pathway. So that's it. What is the innate pharma strategy? Well, firstly, it's about creating near-term value, and that's what we want to achieve with our most advanced proprietary asset, Lactamab, which is in development in T-cell lymphoma. Actually, final CTCL on early PTCL data have been released by the end of 2023 at ASH. On here, we do look forward to the next step, which will be the data on mycosis fungoides, and that will inform the future of this program for the late stage development. Second, we continue to fuel our innovative portfolio with both Enquete and antibody drug conjugates. Enquete is really a core asset. It's a platform which generated several molecules, and as you know, The first molecule in clinic has been advanced by our partner Sanofi, who published in 2003 important first clinical data. We'll come back to that, of course, in greater detail for the SAR443579. But the Yonket portfolio is now expanding with a other assets that have been further licensed in by Sanofi, but also with a proprietary program that was recently announced is now, and this is a second generation of Enquete, which has now been brought to a clinic in phase one in lymphoma. On beyond Enquete, we also advance a second class of agents which are active as a single agent potentially in tumor with antibody drug conjugate, the first one being brought to... We work on bringing it to IND in 2024. Eventually, through partnership, we have Monalizumab door checkpoint inhibitor in phase three on AstraZeneca is pursuing this late stage asset, which will deliver in the next years very important data. So that translates into the portfolio, which is a combination of proprietary products on the partner asset. I will leave it to Sonia to detail the clinical stages on the clinical progress with those assets, especially, firstly, with Lepidamab. Sonia?